Bortezomib and Hyperproteinaemia - a phase IV clinical study of FDA data

Summary:

Hyperproteinaemia is reported as a side effect among people who take Bortezomib (bortezomib), especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months also take Lenalidomide, and have Multiple myeloma.

The phase IV clinical study analyzes which people have Hyperproteinaemia when taking Bortezomib. It is created by eHealthMe based on reports of 30,902 people who have side effects when taking Bortezomib from the FDA, and is updated regularly.

What is Bortezomib?

Bortezomib has active ingredients of bortezomib. eHealthMe is studying from 30,912 Bortezomib users. Check the latest studies of Bortezomib.

What is Hyperproteinaemia?

Hyperproteinaemia (a metabolic disorder characterized by enhanced plasma proline concentrations and urinary excretion) is found to be associated with 77 drugs and 166 conditions by eHealthMe. Check the latest studies of Hyperproteinaemia.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

30,902 people reported to have side effects when taking Bortezomib.
Among them, 16 people (0.05%) have Hyperproteinaemia.

Could Bortezomib cause Hyperproteinaemia?

Among these 16 people:

How long have people been on Bortezomib when they have Hyperproteinaemia? *

What is the gender of people who have Hyperproteinaemia when taking Bortezomib? *

female: 81.25 %
male: 18.75 %

What is the age of people who have Hyperproteinaemia when taking Bortezomib? *

What are other drugs people take besides Bortezomib? *

What are other side effects people have besides Hyperproteinaemia? *

Anaemia (lack of blood): 10 people, 62.50%
Thrombocytopenia (decrease of platelets in blood): 7 people, 43.75%
Weakness: 6 people, 37.50%
Multiple Myeloma (cancer of the plasma cells): 6 people, 37.50%
Disease Recurrence: 6 people, 37.50%
Leukopenia (less number of white blood cells in blood): 6 people, 37.50%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 6 people, 37.50%
Infection: 5 people, 31.25%
Respiratory Tract Infection: 5 people, 31.25%
Aortic Aneurysm (enlargement of an aortic artery caused by a weakening of the artery wall): 4 people, 25.00%

What are the existing conditions these people have? *

Multiple Myeloma (cancer of the plasma cells): 15 people, 93.75%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 1 person, 6.25%
Monoclonal Gammopathy: 1 person, 6.25%
Diabetes: 1 person, 6.25%
Bone Loss: 1 person, 6.25%
Anaemia (lack of blood): 1 person, 6.25%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 1 person, 6.25%

* Approximation only. Some reports may have incomplete information.

Do you take Bortezomib and have Hyperproteinaemia?

- Check whether Hyperproteinaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Bortezomib:

Bortezomib (30,912 reports)

Browse all side effects of Bortezomib:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hyperproteinaemia:

Hyperproteinaemia (77 drugs)

Browse all the conditions that are associated with Hyperproteinaemia:

Hyperproteinaemia (166 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on bortezomib (the active ingredients of Bortezomib) and Bortezomib (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.